The development of COVID-19 treatment

被引:118
|
作者
Yuan, Yongliang [1 ]
Jiao, Baihai [2 ]
Qu, Lili [3 ]
Yang, Duomeng [3 ]
Liu, Ruijuan [1 ]
机构
[1] Zhengzhou Univ, Dept Pharm, Affiliated Hosp 1, Zhengzhou, Henan, Peoples R China
[2] Univ Connecticut, Sch Med, Dept Med, Div Nephrol,Hlth Ctr, Farmington, CT USA
[3] Univ Connecticut, Sch Med, Dept Immunol, Hlth Ctr, Farmington, CT 06269 USA
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
基金
中国国家自然科学基金;
关键词
COVID-19; treatments; antiviral agents; neutralizing antibody therapy; Janus kinase inhibitors; JAK-STAT PATHWAY; OPEN-LABEL; CARDIOVASCULAR-DISEASE; RHEUMATOID-ARTHRITIS; RUXOLITINIB; STANDARD; MULTICENTER; FAVIPIRAVIR; TOFACITINIB; COMBINATION;
D O I
10.3389/fimmu.2023.1125246
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a pandemic named coronavirus disease 2019 (COVID-19) that has become the greatest worldwide public health threat of this century. Recent studies have unraveled numerous mysteries of SARS-CoV-2 pathogenesis and thus largely improved the studies of COVID-19 vaccines and therapeutic strategies. However, important questions remain regarding its therapy. In this review, the recent research advances on COVID-19 mechanism are quickly summarized. We mainly discuss current therapy strategies for COVID-19, with an emphasis on antiviral agents, neutralizing antibody therapies, Janus kinase inhibitors, and steroids. When necessary, specific mechanisms and the history of therapy are present, and representative strategies are described in detail. Finally, we discuss key outstanding questions regarding future directions of the development of COVID-19 treatment.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] COVID-19 and sustainable development
    Munasinghe M.
    Munasinghe, Mohan (mohan@mindlanka.org), 1600, Inderscience Publishers (23): : 1 - 24
  • [42] COVID-19 Drug Development
    Kim, Seungtaek
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2022, 32 (01) : 1 - 5
  • [43] Tetracycline Treatment for COVID-19
    Ohe, Masashi
    Furuya, Ken
    Goudarzi, Houman
    GAZI MEDICAL JOURNAL, 2021, 32 (4A): : 686 - 687
  • [44] Antiviral treatment of COVID-19
    Simsek Yavuz, Serap
    Unal, Serhat
    TURKISH JOURNAL OF MEDICAL SCIENCES, 2020, 50 : 611 - 619
  • [45] Molecules for COVID-19 treatment
    Zeng, Zhigang
    Liao, Changzhou
    Yu, Lei
    CHINESE CHEMICAL LETTERS, 2024, 35 (07)
  • [46] Tocilizumab for the treatment of COVID-19
    Flisiak, Robert
    Flisiak-Jackiewicz, Marta
    Rzymski, Piotr
    Zarebska-Michaluk, Dorota
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2023, 21 (08) : 791 - 797
  • [47] Phytochemicals for the treatment of COVID-19
    Espano, Erica
    Kim, Jiyeon
    Lee, Kiho
    Kim, Jeong-Ki
    JOURNAL OF MICROBIOLOGY, 2021, 59 (11) : 959 - 977
  • [48] Molnupiravir for the treatment of COVID-19
    Santani, Bela G.
    LeBlanc, Brian W.
    Thakare, Ritesh P.
    DRUGS OF TODAY, 2022, 58 (07) : 335 - 350
  • [49] Dexamethasone as a Treatment of COVID-19
    Abdullah Alkattan
    Mahmoud Kandeel
    Dr. Sulaiman Al Habib Medical Journal, 2021, 3 (1) : 7 - 9
  • [50] Tocilizumab for the treatment of COVID-19
    Fernandez-Ruiz, Mario
    Lopez-Medrano, Francisco
    Aguado, Jose Maria
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 431 - 434